Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kimia Farma Persero TbkISX:KAEF +0.45%57 EV-to-EBIT is 31.36 as of Aug. 22, 2026, which is 28% above its 10-year median of 24.52. GuruFocus rates ISX:KAEF with a GF Score™ of 57/100 and a GF Value™ of Rp579.72 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 96 Medical Distribution companies, PT Kimia Farma Persero Tbk ranks worse than 90.63% on this metric.
PT Kimia Farma Persero Tbk (ISX:KAEF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Kimia Farma Persero Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp10,000,918 Mil.
PT Kimia Farma Persero Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp322,856 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk EV-to-EBIT Related Terms
PT Kimia Farma Persero Tbk EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's EV-to-EBIT falls into.
PT Kimia Farma Persero Tbk's current Enterprise Value is Rp10,123,383 Mil.
PT Kimia Farma Persero Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp322,856 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk (ISX:KAEF) has a EV-to-EBIT of 31.36 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Kimia Farma Persero Tbk and its competitors. This is 28% above median its historical median of 24.52. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #87 out of 96 companies in the Medical Distribution industry, placing it in the top 90.6%.
Is PT Kimia Farma Persero Tbk's EV-to-EBIT too high?
PT Kimia Farma Persero Tbk's current EV-to-EBIT of 31.36 is 28% above median its 10-year median of 24.52. The Medical Distribution industry median EV-to-EBIT is 11.28. PT Kimia Farma Persero Tbk's value of 31.36 is 178.1% above this industry median. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #87 out of 96 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #87 out of 96 companies for EV-to-EBIT. This places PT Kimia Farma Persero Tbk in the lower half of its industry. The industry median EV-to-EBIT is 11.28. PT Kimia Farma Persero Tbk's value of 31.36 is 178.1% above this benchmark. While the company's 10-year median is 24.52 vs. the industry median of 11.28, PT Kimia Farma Persero Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.28, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Persero Tbk's current EV-to-EBIT of 31.36 is 178.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Kimia Farma Persero Tbk and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current EV-to-EBIT is 31.36, which is 28% above median its own 10-year median of 24.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.72, compared to a current price of Rp442.00 — trading 23.8% below its estimated fair value. The current EV-to-EBIT is 31.36, which is 28% above median its 10-year median of 24.52 and 178.1% above the Medical Distribution industry median of 11.28. PT Kimia Farma Persero Tbk's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current EV-to-EBIT is 31.36 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp442.00 is trading 23.8% below its estimated GF Value™ of Rp579.72.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
EV-to-EBIT: 31.36 (28% above median its 10-year median of 24.52)
GF Value™: Rp579.72 vs. price of Rp442.00 (23.8% below fair value)
Industry Position: 178.1% above the Medical Distribution median (#87 of 96)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
57GF Score
Get the complete analysis for ISX:KAEF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
